Clinical trials: Orthomyxoviridae Infections
Influenza
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study.
- Trial name
- NCT00402649
- Testing
- Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults
The objective is to assess the humoral and cellular immune response of the VAX102 vaccine delivered IM and SC in a prime-boost regimen at dose levels 1 µg or 2 µg in healthy adults against the influenza A virus M2e antigen after…
- Trial name
- NCT00921206
- Testing
- VAX102
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00665509
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Biologicals
Influenza
A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2008-2009 season.
- Trial name
- NCT00706563
- Testing
- Fluarix™
- Where
- 5 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza With Pneumonia, Invasive Pulmonary Aspergillosis
Influenza Associated Aspergillosis In-depth Investigation
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU.
- Trial name
- PIAS (NCT03748069)
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Influenza
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment…
- Trial name
- PO206 (NCT00979251)
- Testing
- Oseltamivir Phosphate, ADS-8902
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 2 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Viral Upper Respiratory Tract Infection
Randomized Controlled Trial of Vitamin D3 Supplementation for Viral Upper Respiratory Tract Infections (URI) Prevention
Background: Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during the winter may cause increased susceptibility to infections, particularly viral upper respiratory tract infections…
- Trial name
- NCT00656929
- Testing
- Vitamin D3
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Winthrop University Hospital
Influenza, Human
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
The goal of this clinical trial is to evaluate the safety and immune responses of three different dose levels a self-amplifying RNA pandemic influenza vaccine (ARCT-2304) in adults.
- Trial name
- NCT06602531
- Testing
- ARCT-2304, Control vaccine younger adults, Control vaccine older adults
- Where
- 4 sites in United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Influenza
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza
This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.
- Trial name
- NCT01068912
- Testing
- Favipiravir
- Where
- 228 sites in United States, Australia and 5 more
- Volunteers
- 530 people
- Sponsor
- MDVI, LLC
Influenza
Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations
This is a Phase II open-label study in approximately 240, and up to 400, healthy males and non-pregnant females, aged 6 months to 17 years.
- Trial name
- NCT02100436
- Testing
- Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
- Where
- 8 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
People who are infected with the influenza virus may develop respiratory illnesses, such as pneumonia, or other life-threatening complications. Currently, there are four antiviral medications that are used to treat influenza.
- Trial name
- NCT01314911
- Testing
- Oseltamivir
- Where
- 51 sites in United States, Argentina and 1 more
- Volunteers
- 716 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Upper Resp Tract Infection
Climate Change Trends and Their Impact on the Seasonal Upper Respiratory Tract Disease Burden
Investigators assume that global climate changes can influence upper respiratory tract infection peak prevalence, which may have significant clinical implication, for example, by adjusting seasonal Influenzas' vaccine timing.
- Trial name
- NCT07767019
- Testing
- No Intervention: Observational Cohort
- Where
- Israel
- Volunteers
- 5,000 people
- Sponsor
- Barzilai Medical Center
Influenza, Human
Dose Finding Study of Single Dose GHB11L1 in Healthy Adults
The purpose of this phase IIa trial is to evaluate the immunogenicity of a single dose of GHB11L1 administered by liquid nasal spray for vaccination against influenza A (H1N1) virus.
- Trial name
- GHB-CS07 (NCT01078701)
- Testing
- GHB11L1
- Where
- Austria
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza
Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older
The purpose of this study is to determine the efficacy, safety and tolerability of the liquid formulation of CAIV-T against culture confirmed influenza illness in adults aged 60 years and older.
- Trial name
- NCT00217230
- Testing
- CAIV-T
- Where
- South Africa
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects
This study will evaluate safety and immunogenicity of surface, antigen, inactivated, influenza vaccine produced in mammalian cell culture when administered to adult and elderly subject.
- Trial name
- NCT01422512
- Testing
- seasonal influenza vaccine
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)
The purpose of this study is to determine whether GC3110A (a QIV) is effective compared to GC Flu Pre-filled Syringe Inj. (a marketed TIV) after single intramuscular administration in Korean healthy adults.
- Trial name
- NCT02121782
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Chronic Lymphocytic Leukemia
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
The goal of this clinical study is to learn if Pegasys (pegylated interferon) or Roferon (interferon) can make the Trivalent Inactivated Influenza vaccine (TIV) more effective in increasing the body's immune reaction against the…
- Trial name
- NCT00962715
- Testing
- Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Interferon (IFNα, Roferon-A)
- Sponsor
- M.D. Anderson Cancer Center
Influenza Immunization, Health Volunteers
A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire
This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine…
- Trial name
- NCT06765187
- Testing
- Trivalent Recombinant Influenza Vaccine
- Where
- United States
- Volunteers
- 1,007 people, healthy volunteers welcome
- Sponsor
- Sanofi
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population
This is a multiple sites phase II trial, randomized, observer-blind, dose ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-based Seasonal VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02236052
- Testing
- Non-adjuvanted low dose of quadrivalent VLP vaccine, Non-adjuvanted medium dose of quadrivalent VLP vaccine, Non-adjuvanted high dose of quadrivalent VLP vaccine
- Where
- 3 sites in Canada
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Influenza Burden Assessment in the United Kingdom, 1996-2008
The study will assess the burden of influenza by age, risk status, vaccination status and influenza subtype, in order to create a complete profile of the burden of influenza-related morbidity and mortality in United Kingdom from…
- Trial name
- NCT01520935
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.